United Immunity Co. operates in the biohealth sector, specializing in the development of advanced immunotherapies and vaccines. The company leverages cutting-edge nanotechnology to create potent anti-tumor T cell activating therapies aimed at conquering intractable solid cancers, particularly those resistant to conventional treatments. Additionally, United Immunity is at the forefront of developing next-generation SARS-CoV-2 nanoparticle vaccines, addressing the ongoing global health crisis. The primary clients include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development, clinical trials, and partnerships with larger pharmaceutical firms for commercialization. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.

Keywords: nanotechnology, immunotherapy, cancer treatment, COVID-19 vaccine, biohealth, T cell activation, nanoparticle, clinical trials, pharmaceutical partnerships, advanced therapies.